Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier joins Proactive's Stephen Gunnion with details of an exclusive sales agreement with PharmAla Biotech Holdings for its pharmaceutical-grade psilocybin to appropriately licensed clinical researchers.
Lanthier telling Proactive that Mindset has developed a patent-pending, highly scalable psilocybin synthesis technology.
A cost-effective supply of first-generation psychedelic therapeutics is essential to the overall development of the medical psychedelic space, and Mindset is eager to help meet this increased demand, he adds.